Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2025)

Crinetics Pharmaceuticals has reported Research & Development over the past 9 years, most recently at $85.1 million for Q4 2025.

  • Quarterly results put Research & Development at $85.1 million for Q4 2025, up 27.77% from a year ago — trailing twelve months through Dec 2025 was $332.1 million (up 38.27% YoY), and the annual figure for FY2025 was $332.1 million, up 38.27%.
  • Research & Development for Q4 2025 was $85.1 million at Crinetics Pharmaceuticals, down from $90.5 million in the prior quarter.
  • Over the last five years, Research & Development for CRNX hit a ceiling of $90.5 million in Q3 2025 and a floor of $17.6 million in Q1 2021.
  • Median Research & Development over the past 5 years was $42.2 million (2023), compared with a mean of $47.8 million.
  • Biggest five-year swings in Research & Development: soared 62.5% in 2021 and later rose 23.17% in 2023.
  • Crinetics Pharmaceuticals' Research & Development stood at $24.6 million in 2021, then surged by 50.35% to $37.0 million in 2022, then increased by 23.22% to $45.6 million in 2023, then skyrocketed by 46.04% to $66.6 million in 2024, then grew by 27.77% to $85.1 million in 2025.
  • The last three reported values for Research & Development were $85.1 million (Q4 2025), $90.5 million (Q3 2025), and $80.3 million (Q2 2025) per Business Quant data.